单次 ibogaine 治疗一年随访:退伍军人 PTSD、抑郁与焦虑改善多数维持
One year after taking ibogaine, veterans find continued relief from PTSD
斯坦福医学院团队在 Translational Psychiatry 发表的 12 个月随访显示,接受单次 ibogaine 治疗的特种部队退伍军人一年后多数仍维持 PTSD、抑郁和焦虑症状改善。
观察性随访给出单次 ibogaine 治疗后一年症状改善的维持数据,同时明确未控制后续干预。
A few years ago, 30 special forces veterans suffering for years with the psychiatric consequences of multiple traumatic brain injuries—including post-traumatic stress disorder, depression and anxiety—traveled to Mexico to undergo a little-known psychedelic therapy called ibogaine.
Derived from the root of a West African shrub and long used in traditional spiritual ceremonies, ibogaine had been gaining a reputation for helping traumatized veterans at the end of their rope. A group of them had agreed to be studied by Stanford Medicine researchers before and after the therapy.
Patrick Flatley, a former Green Beret who served multiple tours in Iraq and Afghanistan, was among them. He had joined the U.S. Army at age 19 and racked up head injuries early and often—first as a paratrooper jumping out of airplanes with 70 pounds (32 kilograms) strapped to his back, then as a mortarman handling explosive weapons.
In 1994, he was a Green Beret sniper when two U.S. Army helicopters were mistakenly shot down by U.S. Air Force fighter jets in northern Iraq. Flatley had frequently ridden on those helicopters, but that day a last-minute personnel change bumped him from his spot.
He was plagued by nightmares in the aftermath of the accident. "It was the same over and over. I never had a good dream for 25 years," he said. Over more tours, he accumulated more head traumas and physical injuries, including a broken back. He retired from the Army but became so tense and angry that some mornings he awoke with a mouth full of blood, having broken his molars in his sleep. Bustling crowds, driving in traffic or the whir of a helicopter overhead sent him into fight-or-flight mode.
It was the ibogaine therapy, he said, that finally allowed him to come home from the war.
Ibogaine shows promise
The short-term effects of the therapy, reported by Stanford Medicine researchers in early 2024, were swift and dramatic. Of the 23 veterans who had a diagnosis of post-traumatic stress disorder before treatment, 19 achieved remission within days—meaning they no longer met the clinical criteria for the disorder.
"As soon as the team started to see these improvements and the magnitude of the improvements in these veterans, which I don't think anyone necessarily expected, they started quickly planning for the long-term follow-up element," said Jennifer Lissemore, Ph.D., a postdoctoral scholar who joined the team to help analyze the one-year follow-up of the veterans.
In a study published Aug. 12 in Translational Psychiatry, researchers reported that for most participants, the benefits that followed a single ibogaine treatment appeared to remain robust one year later.
"Over the course of the year, there were improvements that weren't just rapid, but surprisingly sustained for what we normally see in psychiatry," said Camarin Rolle, Ph.D., clinical assistant professor of psychiatry and behavioral sciences and co-senior author of the new study. "We saw persistent reductions in PTSD, depression, anxiety and functional disability."
During the treatment, participants were medically monitored as they took oral ibogaine and received infusions of magnesium to protect against heart complications that have been associated with ibogaine.
For Flatley, who underwent the treatment in 2022, the transformation felt immediate. "My head started to tingle. I could feel my brain getting soothed, like it was getting what it needed," he recalled of the psychedelic experience, which can last 24 to 72 hours.
One month after treatment, the participants' PTSD symptoms had improved on average by 88%, depression symptoms by 87% and anxiety symptoms by 81%.
Twenty-five of the veterans completed the one-year follow-up, which included psychiatric assessments at three, six, nine and 12 months administered by a neuropsychologist. The researchers found that among participants who achieved remission soon after the treatment, the likelihood of sustained remission at 12 months was 84% for PTSD, 66% for depression and 61% for anxiety.
The researchers stopped following the veterans after one year, but for about four years post-ibogaine, Flatley did not have a nightmare about the war. His PTSD isn't gone, but it's manageable.
"Before I would wake up and just be angry about something that happened 30 years ago, 20 years ago, 10 years ago—and it was consuming me," he said. "Now, I can say, 'I'm not spending any more time being mad.'"
Only observational
The results are the most extensive evidence to date of ibogaine's long-term effects on PTSD, depression and anxiety. The researchers caution, however, that because the study was only observational, they did not control for additional interventions or psychedelic use after the first month. Over the next 11 months, 12 participants received therapy or counseling, three took psychotropic medications like standard antidepressants, and 23 took at least one psychedelic substance, which ranged from microdosing to dedicated psychedelic retreats.
(The most common psychedelic was 5-MeO-DMT, a short-acting compound that induces feelings of profound awe. It's typically administered on the third day of ibogaine therapy, but veterans in the study agreed to delay taking it until after the first month.)
"Therefore, we couldn't say that this one-year effect is due solely to that initial ibogaine experience," Rolle said.
Nevertheless, their analysis of the data suggests long-lasting improvements overall, even for participants who did not undergo additional interventions.
"For a single treatment to deliver 12 months of relief to some people is very exciting," said Lissemore, who is co-lead author of the new study. "Ideally, if we want this to become a treatment that people can pursue, it would be something that you're not having to repeat every month or two. If a treatment is known to have durable effects over the course of a year or more, that gives you much more reason to pursue it."
The study's other co-lead author is Afik Faerman, Ph.D., a former postdoctoral scholar in psychiatry. The other co-senior author, Nolan Williams, M.D., professor of psychiatry and behavioral sciences, led the work until his death last year.
Growing support
The durability of the response could better justify the demands of ibogaine therapy, which often entails a grueling psychedelic trip and logistical challenges. The psychedelic experience typically involves revisiting past traumas in a dreamlike state and comes with cardiac and other risks that must be carefully screened for and monitored.
Ibogaine has been a Schedule I drug since 1970, meaning patients must travel to Mexico, Canada or a few other countries that offer legal ibogaine treatments, and researchers in the U.S. can't study the drug directly. But interest in ibogaine therapy has grown in recent years, in part due to the promising results from the 2024 Stanford Medicine study and advocacy from groups like Veterans Exploring Treatment Solutions.
In April, President Donald Trump signed an executive order to accelerate research on and Food and Drug Administration approval of psychedelic drugs for serious mental illness. It cited the disproportionate toll of mental illness on veterans: More than 6,000 veterans die each year from suicide, a rate double that of the nonveteran adult population.
Flatley has seen that toll among his friends. Since his ibogaine experience, he's become somewhat of an ambassador, helping dozens of veterans seek out the therapy.
Encouraged by the latest findings, the researchers already have plans to study ibogaine in a different population: Ukrainian refugees, mostly women, with war-related PTSD. They hope that added momentum from the executive order will allow them eventually to study ibogaine up close and better understand the neurological mechanisms at work, which are still unclear.
An analysis of brain imaging from the veterans found small structural changes one month after treatment, including slight average increases in cortical thickness (the outer surface of the brain responsible for reasoning and language) and subcortical volume (deeper brain regions responsible for emotion and memory) and a slight decrease in predicted brain age. The researchers caution that these findings are preliminary and do not yet explain how ibogaine produces its effects.
"We are optimistic the future of ibogaine research will lead to effective treatment for individuals suffering the debilitating effects of PTSD," Rolle said.
Publication details
Afik Faerman et al, Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in special operations veterans with traumatic brain injuries, Translational Psychiatry (2026). DOI: 10.1038/s41398-026-04327-5
Journal information: Translational Psychiatry
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: One year after taking ibogaine, veterans find continued relief from PTSD (2026, October 7) retrieved 7 October 2026 from https://medicalxpress.com/news/2026-10-year-ibogaine-veterans-relief-ptsd.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com